Research programme: factor Xa inhibitors - Morphochem

Drug Profile

Research programme: factor Xa inhibitors - Morphochem

Alternative Names: MCM-09; MCM-16; MCM-17; Orally available antithrombotics - Morphochem

Latest Information Update: 28 Jul 2010

Price : $50

At a glance

  • Originator Morphochem AG
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Arterial thrombosis; Cancer metastases; Venous thrombosis

Most Recent Events

  • 28 Jul 2010 Discontinued - Preclinical for Arterial thrombosis in Germany (PO)
  • 28 Jul 2010 Discontinued - Preclinical for Arterial thrombosis in Germany (unspecified route)
  • 28 Jul 2010 Discontinued - Preclinical for Cancer metastases in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top